[go: up one dir, main page]

AU2001256278A1 - Use of cse inhibitors for treating heart failure - Google Patents

Use of cse inhibitors for treating heart failure

Info

Publication number
AU2001256278A1
AU2001256278A1 AU2001256278A AU5627801A AU2001256278A1 AU 2001256278 A1 AU2001256278 A1 AU 2001256278A1 AU 2001256278 A AU2001256278 A AU 2001256278A AU 5627801 A AU5627801 A AU 5627801A AU 2001256278 A1 AU2001256278 A1 AU 2001256278A1
Authority
AU
Australia
Prior art keywords
heart failure
treating heart
cse inhibitors
cse
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001256278A
Inventor
Johann Bauersachs
Hilmar Bischoff
Georg Ertl
Daniela Fraccarollo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000119143 external-priority patent/DE10019143A1/en
Priority claimed from DE2000119272 external-priority patent/DE10019272A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001256278A1 publication Critical patent/AU2001256278A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001256278A 2000-04-18 2001-04-11 Use of cse inhibitors for treating heart failure Abandoned AU2001256278A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10019143 2000-04-18
DE2000119143 DE10019143A1 (en) 2000-04-18 2000-04-18 Medicament for prophylaxis or treatment of cardiac insufficiency, comprising cholesterol synthesis enzyme inhibitor, preferably cerivastatin
DE10019272 2000-04-19
DE2000119272 DE10019272A1 (en) 2000-04-19 2000-04-19 Medicament for prophylaxis or treatment of cardiac insufficiency, comprising cholesterol synthesis enzyme inhibitor, preferably cerivastatin
PCT/EP2001/004135 WO2001078747A1 (en) 2000-04-18 2001-04-11 Use of cse inhibitors for treating heart failure

Publications (1)

Publication Number Publication Date
AU2001256278A1 true AU2001256278A1 (en) 2001-10-30

Family

ID=26005362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001256278A Abandoned AU2001256278A1 (en) 2000-04-18 2001-04-11 Use of cse inhibitors for treating heart failure

Country Status (2)

Country Link
AU (1) AU2001256278A1 (en)
WO (1) WO2001078747A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50377B (en) 1999-08-30 2009-11-10 Sanofi-Aventis Deutschland Gmbh., RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND THEIR APPLICATIONS
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
AU2006223212A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
CZ20011035A3 (en) * 1998-09-30 2001-10-17 Warner-Lambert Company Method for preventing or delaying catheter-based revascularization in patients suffering from coronary artery disease

Also Published As

Publication number Publication date
WO2001078747A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
AU7906100A (en) Use of retigabin for treating neuropathic pain
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2001233081A1 (en) Composition for treatment of stress
AU6111000A (en) Inhibitors of viral helcase
AU2001271782A1 (en) Use of substituted insole compounds for treating excessive intraocular pressure
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2001286983A1 (en) Method of treatment
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU1878201A (en) Composition for the treatment of damaged tissue
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AUPP910699A0 (en) Inhibitor of lipoxygenase pathways
AU2001256278A1 (en) Use of cse inhibitors for treating heart failure
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
AU2001262177A1 (en) Method of treatment
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU4598400A (en) Method of treatment
AU4985200A (en) Methods of treating hypertension
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU3757200A (en) Treatment of pulmonary hypertension
AU2001253560A1 (en) Methods of treatment
AU8626398A (en) Inhibitors of the phosphodiesterase-4 for the treatment of allergic rhinitis
AU2289100A (en) Binding partners for 5-ht5-receptors for the treatment of migraine